Parkinson's disease (PD) is a neurodegenerative disorder that affects millions of people
worldwide. Two hallmarks of PD are the accumulation of alpha‐synuclein and the loss of …

As a neuromodulator, the neurotransmitter acetylcholine plays an important role in cognitive,
mood, locomotor, sleep/wake, and olfactory functions. In the pathophysiology of most …

Objective: To validate an in vivo method for mapping acetylcholinesterase (AChE) activity in
human brain, preparatory to monitoring inhibitor therapy in AD. Background: AChE activity is …

Background Acetylcholinesterase activity, a marker for degeneration of the central
cholinergic system, has consistently been reported, in necropsy brain studies, to be reduced …

Background REM sleep behaviour disorder (RBD) occurs frequently in patients with
synucleinopathies such as Parkinson's disease, dementia with Lewy body, or multiple …

We measured brain acetylcholinesterase activity in 16 patients with Parkinson's disease
(PD), 12 patients with progressive supranuclear palsy (PSP), and 13 age‐matched controls …

We measured brain acetylcholinesterase activity in 30 patients with Alzheimer's disease
(AD) and 14 age‐matched controls by positron emission tomography (PET) and using a …

Objectives: Cholinergic projections to cerebral cortical and subcortical regions are
decreased in Parkinson disease (PD), but not evaluated in the parkinsonian syndromes of …

Amyloid-β (Aβ) plaques are a neuropathological hallmark of Alzheimer's disease (AD);
however, a significant number of cognitively normal older adults can also have Aβ plaques …

Positron emission tomography (PET) imaging in clinical neurology serves several purposes:
differential diagnosis, especially in the early stage of neurologic disorders, description of …